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Abstract 
Purpose 
The purpose of this study has been to investigate the results of above-knee 
prosthetic femoropopliteal bypass surgery and to identify risk factors for 
complications and graft failure. The influence of comorbidity, degree of chronic leg 
ischaemia, preoperative angiographic run-off score and intraoperative flow 
measurements on long-term results were investigated. Furthermore, local infections 
and the outcome of treating occluded prosthetic grafts were studied.  
 
Methods 
Two-hundred-and-thirty-seven patients (156 men, 81 women) were subjected 
to 252 above-knee prosthetic femoropopliteal bypass operations at Haukeland 
University Hospital between Jan 1990 and Dec 2001. One hundred and forty-one 
graft implantations (129 patients) were done for intermittent claudication and 111 
(108 patients) for critical ischaemia. Patient data were prospectively recorded in a 
database registry. Some data were supplemented from patients records. Occlusion 
dates, complications, re-operations including amputations, and mortality were also 
recorded. Patient characteristics, anatomical risk factors and intraoperative flow 
measurements were analysed for impact on results after surgery.  
Survival, limb salvage and patency rates were analysed with the Product limit 
method and illustrated as Kaplan-Meier curves. The risk factors were subjected to 
univariate analysis using the log rank test for impact on survival, limb salvage and 
patency rates. Variables approaching significance were included in multivariate 
analysis performed with the Cox proportional hazard model. 
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Results 
Paper I. Surgical site infection was recorded after 7.8 % of the operations and graft 
infection after 12 %. The risk of developing a local infection was significantly 
correlated with postoperative lymph fistula. Redo surgery was associated with graft 
infection. Graft infections caused by Staph. Aur. always warranted surgery, either 
local revision or graft excision.  
Paper II. For grafts implanted for intermittent claudication, the assisted primary 
patency rates were 62 % at 2 years and 44 % at 5 years. The 5-year patency rate for 
smokers was 24 % versus 67 % for non-smokers (p < 0.01). A previous history of 
cerebral infarction was significantly associated with reduced graft patency. 
Preoperative s-creatinine > 125 mmol/L was significantly associated with reduced 
survival. 
Paper III. The 30-day mortality rate of patients operated for critical ischaemia was 
5.5 %. The 2- and 5-year survival was 72 % and 42 %, whereas the limb salvage rates 
at 2 and 5 years were 83 % and 73 %, respectively. The 2-year primary patency rate 
for smokers was 38 % versus 62 % for non-smokers (p = 0.018, hazard ratio 2.18). 
Smoking and tissue loss were significantly associated with reduced secondary 
patency. 
Paper IV. Basal flow measurements were not related to patency. The 2- and 5-year 
patency rates for grafts with a papaverine flow < 500 ml/min were 48 % and 18 % 
compared with 66 % and 52 % for grafts with a papaverine flow ≥ 500 ml/min (p = 
0.012, hazard ratio 2.6). Two and 5-year patency rates for smokers vs non-smokers 
were 44 % and 18 % vs 69 % and 54 %. Smoking (p = 0.008, hazard ratio 2.38) and 
poor run-off score (p = 0.009, hazard ratio 2.38) were independent risk factors for 
reduced patency. Poor run-off score did not correlate with low values of measured 
basal or papaverine flow. 
Paper V. Half the 24 initial procedures to restore patency of occluded grafts 
originally implanted for critical ischaemia failed within a month. Outcome of second- 
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or third-time redo procedures were similar. Primary patency rates of all 55 redo 
procedures were 32 % at three months, 28 % at six months and 12 % at 12 months. 
The results of thrombectomy and thrombolysis were similar. Re-opened grafts 
additionally treated for an underlying anastomotic stenosis had significantly better 
patency, as compared with re-opened grafts without a pre-existing stenosis (p = 
0.027, hazard ratio 2.813). 
 
Conclusions 
The results regarding survival, limb salvage and patency are comparable to 
previous reports. The results underline that a long observation period is necessary to 
achieve full overview of complications and the impact of risk factors. 
Infectious complications after prosthetic femoropopliteal bypass in the study 
group were higher than previously reported. The results suggest that a selective 
approach should be taken towards excision of infected femoropopliteal prostheses 
according to the clinical presentation of the graft infection and the type of bacteriae 
involved. 
A conservative attitude is recommended towards placing a prosthetic graft in 
the above-knee femoropopliteal position for intermittent claudication. The finding of 
reduced patency rates in patients with a history of a cerebral insult operated for 
intermittent claudication need further studies to be verified. Patients with intermittent 
claudication and renal impairment reveal poor survival, indicating renal impairment 
as a relative contraindication for surgical treatment. Smokers have inferior patency 
rates when operated for intermittent claudication as well as for critical ischaemia. 
Poor angiographic run-off score was also associated with inferior patency rates. 
These findings indicate that prosthetic femoropopliteal bypass is not very suitable for 
these groups of patients. Furthermore, the poor secondary patency rates of smokers as 
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well as for patients with tissue loss suggest that these patients may benefit from 
alternative treatment modalities to re-opening an occluded bypass.  
A papaverine flow of < 500 ml/min is associated with reduced patency. 
Additional antithrombotic medication and frequent follow-up may be considered for 
these grafts. Redo procedures for occluded grafts originally implanted for critical 
ischaemia are of limited value and cannot be recommended except in cases with a 
proven graft-related stenosis. Other cases in need of re-intervention should be treated 
with either a new arterial reconstruction or an amputation.  
Based on the findings in this study, the following issues must be evaluated 
when offering an above-knee prosthetic femoropopliteal bypass for chronic limb 
ischaemia: patient comorbidity, smoking, degree of ischaemia and angiographic run-
off score. Careful selection of patients subjected to above-knee prosthetic bypass 
surgery for chronic ischaemia is mandatory to achieve the optimal gain of the 
operation. 
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1. Introduction 
 
1.1 Re-occlusions and complications in infrainguinal 
vascular surgery 
The durability of arterial reconstructions (both surgical and endovascular) 
performed below the groin is more limited (1-6) contrasted to that of reconstructions 
performed above the groin(7-9). Thus the anatomical region below the inguinal 
ligament constitutes an Achilles heel in vascular surgery.  
The durability of vascular reconstructions is often reported in terms of 
patency. The term “patency” is explained in chapter 3.11.3. Limb salvage (3.11.2) 
and survival (3.11.1) are also often studied in vascular patients. Complications are 
less frequently reported despite the fact that these are well known to vascular 
surgeons.  
The relatively large number of prosthetic femoropopliteal bypass operations 
performed at our department during the study period generated numerous 
complications and re-do procedures. Apparently, there was a need for scrutiny of the 
treatment policy and of the procedures related to the operations. This need for 
reevaluation initiated this study. 
 
1.2 Femoropopliteal and systemic atherosclerosis  
Arterial occlusions of the superficial femoral and the popliteal artery are 
common. Femoropopliteal atherosclerotic lesions may account for approximately 50 
% of target lesions treated in a vascular clinic(10). However, this percentage may 
vary according to local treatment policy. Isolated femoropoliteal atherosclerotic 
lesions lead in most cases to intermittent claudication, whereas concomitant 
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significant lesions at other anatomical levels, i.e. multi-level disease, more often lead 
to critical limb ischemia(11).  
Femoropopliteal occlusions are classified in four classes, TASC A-D, 
according to the Transatlantic Consensus Document (Table I, Appendix)(11). All 
cases included in the present studies were occlusions, either TASC-C or -D lesions.  
Up to 50 % of patients having symptomatic femoropoplital atherosclerosis 
have concomitant symptomatic coronary disease and 10 % have cerebrovascular 
disease(12,13). Two thirds of patients with peripheral arterial disease die from 
coronary disease and 10 % from stroke(14). These facts clearly demonstrate 
atherosclerosis as a systemic disease.  
 
 
Figure 1. An angiogram demonstrating bilateral occlusion of the superficial 
femoral artery. 
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1.3 Peripheral bypass surgery: Historical background 
Prostetic grafts for use in peripheral bypass surgery were developed in the 
United States in the beginning of the 1950’s. In 1952, Voorhees, Jaretzki and 
Blakemore’s pioneering work with porous vinyon-“N”-prosthesis ushered the 
development of peripheral vascular surgery and the use of prosthetic grafts (15,16). 
In 1954, the nylon prosthesis was introduced by Edwards et al (17,18). Shortly 
thereafter, Edwards and Tapp devised the crimping process for arterial prostheses 
(18-20). However, the nylon grafts proved unsatisfactory because they lost up to 80 
% of their tensile strength after experimental implantation. In 1956, the Teflon graft 
was developed. This graft proved to have a much longer tensile strength durability as 
compared with nylon(17,18). Concomitantly, the Dacron prosthesis (polyester) was 
found to be the most promising graft at that time, according to experiments performed 
on a number of materials by DeBakey et al (21,22). Based on these findings, the 
Dacron DeBakey vascular prosthesis was developed and introduced in January 1957. 
The first prosthetic femoropopliteal bypass in Norway was performed in 1958, 
using the Edwards-Tapp’s crimped nylon prosthesis. In 1964, the norwegian surgeon 
Karl Victor Hall reported dissappointing long-term results of 42 cases in which “the 
plastic graft” was used as bypass for femoropopliteal obstruction, concluding that 
these grafts were not suitable for this use (23).  
In 1972, polytetrafluoroethylene (PTFE) (Gore-Tex®) wire insulation was first 
implanted in arteries and veins of dogs in Denver, Colorado(24). The PTFE-graft was 
subsequently modified including fibrillar arrangement, wall thickness, and pore size 
leading to the development of a vascular prosthesis with tissue ingrowth, viable 
neointima and acceptable patency rates. 
During the years a variety of graft types of different materials have been 
manufactured followed by optimistic and promising reports of graft performance. 
However, several randomised controlled trials comparing different prosthetic grafts 
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concluded that the results were similar, i.e. no prosthetic graft material has been 
proven superior to the others (25,26).  
The first prosthetic femoropopliteal bypass at Haukeland University Hospital 
was performed in 1975. The patient was a 66 year old male with intermittent 
claudication. The graft was made of non-impregnated polyester. Two months 
postoperatively, the graft was excised due to graft infection but amputation was not 
required. The patient died from a myocardial infarction two years later.  
In many vascular clinics during the 1980’s and 1990’s, prosthetic 
femoropopliteal bypass surgery was standard treatment for occlusive arterial disease. 
After the introduction of the method at Haukeland University Hospital in 1975, the 
operation was only occasionally performed until 1990 when its use increased. The 
use of prostheses in above-knee femoropoplital bypass surgery reached a top in our 
department in 1995 (Figure 2).  
During the years 1990 – 2001 a vein was used as conduit in only 27 above-
knee femoropopliteal bypasses, as contrasted to the use of 252 prostheses during the 
same period. The annual number of prosthetic femoropopliteal bypass declined to a 
minimum after the year 2000 (Figure 2), and since then the preferred graft has been 
autologous vein. However, prosthetic femoropopliteal bypass is still used in selected 
cases. Therefore, the knowledge of risk factors for complications and failure after 
prosthetic bypass are still of value.  
Current indications for the use of prosthetic grafts in the above-knee 
femoropopliteal position are discussed further in chapter 4.1.4.1 and 4.1.4.2. 
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Figure 2.  The annual numbers of above-knee prosthetic femoropopliteal bypass 
operations at Haukeland University Hospital 1990 – 2001. 
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
Year
0
5
10
15
20
25
30
35
N
um
be
r
 16 
2. Aims of the Thesis 
The overall aim of this Thesis is to investigate the results of above-knee 
femoropopliteal prosthetic bypass and to identify risk factors for complications and 
graft failure. The aims of the studies in this Thesis are: 
Study I: to investigate the incidence of and to identify risk factors for surgical 
site infections and graft infections. 
Study II: to investigate the impact of comorbidity on long-term results of above-
knee femoropopliteal prosthetic bypass for intermittent claudication. 
Study III: to investigate the impact of patient characteristics on long-term results 
above-knee femoropopliteal prosthetic bypass for critical ischaemia. 
Patient characteristics include comorbidity, degree of lower limb 
ischemia and preoperative angiographic run-off score. 
Study IV: to investigate the impact of intraoperative transit time flow 
measurements on short- and long-term results of above-knee 
femoropopliteal prosthetic bypass. 
Study V: to investigate the outcome of re-opening occluded prosthetic grafts 
implanted for critical limb ischaemia. 
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3. Patients and Methods 
 
3.1 Study design  
The studies are based on prospectively recorded patient data in a 
vascular registry maintained by the department and supplemented with data 
from patient records. The data were retrospectively analysed. 
 
3.2 Patients 
The studies I-V include 237 patients (156 men, 81 women) subjected to 
252 above-knee prosthetic femoropopliteal bypasses from Jan 1990 – Dec 
2001. The patients were treated at the Surgical Clinic, Section for Vascular 
Surgery, Haukeland University Hospital, Bergen, Norway. No patients 
operated with femoropopliteal prosthetic bypass in the period were excluded.  
For patients with vascular disease, Haukeland University Hospital 
serves as a primary hospital for 400.000 people and as a secondary and tertiary 
hospital for 800.000. No vascular surgery was done elsewhere in the primary 
uptake area during the study period. 
 
3.3 Risk factors for complications and graft failure 
3.3.1 Patient comorbidity. Patient comorbidities were defined as those 
prospectively recorded in the vascular registry.  
3.3.1.1  Heart disease (Study I).  Heart disease warranting treatment was 
considered significant and was recorded in the vascular registry. Thus, 
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coronary disease, valvular pathology, arrythmia, congestive heart failure etc. 
were recorded as the same risk factor. No information about the function class 
of the patient was recorded. Symptomatic coronary disease was not specified 
in Study I.  For studies II – V, information about coronary disease was 
extracted from the vascular registry. Coronary disease was recorded if the 
patient had had a myocardial infarction, a previous aortocoronary bypass or a 
percutaneous coronary intervention (PCI) or present angina pectoris. The 
coronary disease was not further classified.  
3.3.1.2  Hypertension (Study I-V). Hypertension was recorded if medically 
treated. This definition was chosen when the vascular registry was established. 
The argument for not recording “untreated hypertension” is that measurements 
of high blood pressure without medication may represent falsely elevated 
blood pressure (“white coat hypertension”) due to a stress response in the 
patient (27). 
3.3.1.3  Cerebrovascular disease (Study I – V). Cerebrovascular disease was 
defined as earlier history of cerebral insults. No distinction was made between 
major and minor strokes. It was not specified whether or not disability was 
present, which may have affected mobility. 
3.3.1.4  Diabetes mellitus (Studies I – V). Both diabetes mellitus type 1 and 
type 2 were recorded as a risk factor if the condition was medically treated. No 
distinction was made between the two subgroups of diabetes mellitus. Thus, 
diet-controlled diabetes 2 was not recorded. Our definition of diabetes as a risk 
factor is debatable. Except s-glucose measurements, no screening 
investigations were done for detecting diabetes mellitus. Since 2005, we have 
routinely analysed HbA1c in all patients admitted to our clinic. In addition, S-
Insuline is measured according to a protocol. The value of detecting diabetes 
mellitus in vascular patients is well documented (28,29). 
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3.3.1.5  Lung disease (Study I). In study I, chronic lung disease was recorded. 
This information is inaccurate, since the patients had actually had COPD, 
which also was registered in the vascular database. This is corrected in study II 
– V. 
3.3.1.6  COPD (Study II – V). Chronic obstructive pulmonary disease was 
recorded if the patient received medical treatment. The presence of COPD 
denotes a reduced respiratory status and this information is of importance since 
some of these patients are at high risk for surgery. The frequency of COPD is 
higher among smokers than non-smokers (30). COPD is not proven to affect 
results of peripheral vascular surgery. However, COPD may lead to secondary 
polycytaemia (31) and thus increased risk of thrombosis (32).  
3.3.1.7  Renal impairment (Study I – V). This was defined as serum-creatinine 
above 125 μmol/L. The condition is known to increase the risk of 
atherosclerosis, inflammation, endothelial dysfunction and platelet activation 
(33). No distinction was made between patients with mild and moderate renal 
impairment or renal failure. Such a distinction may be of importance for 
grading risk. The association between renal failure and poor results of above-
knee prosthetic femoropopliteal bypass is previously reported (34,35).   
 
3.3.2 Smoking 
The patient was classified as smoker if he had been smoking regularly 
within the last five years prior to surgery. This definition is debatable, but was 
chosen when the vascular registry was established. It has been reported that a 
quarter of the patients untruthfully claim having stopped smoking when 
examined with serum markers, especially s-isothiocyanate (36,37). 
Measurement of cotinine in urine has also been reported to be a reliable 
method for obtaining information on smoking status (38). However, the use of 
nicotine substitutes may be a confounder if laboratory analyses are chosen to 
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investigate smoking habits (39). We believe that patients are more prone to 
answer truthfully if they are asked if they have been smoking during the last 
five years as compared with smoking at the time of surgery. However, we 
regard smoking to be under-reported in the present material. Smoking status is 
an important preoperative information, since smoking puts patients at a higher 
risk for surgery and the results after surgery are correlated to the daily number 
of cigarettes postoperatively (36,40,41). According to a recently published 
meta-analysis, smokers have a three-fold increase in risk for graft failure after 
vascular surgery compared with non-smokers (42).  
  
3.3.3 The degree of chronic leg ischemia 
The degree of arterial insufficiency in the lower extremity can be 
stratified into four stages in non-diabetic patients according to the Fontaine 
classification (Table II, Appendix)(43).  
3.3.3.1     Intermittent claudication. 
Intermittent claudication (study I, II and IV) represents Stage 2 in the 
Fontaine classification. The patient experiences exercise-induced pain, 
numbness or fatigue in the muscles of the hip, thigh and/or calf. Typically, the 
symptoms disappear after rest, and then the patient is able to walk again.  
Exercise-induced ischaemia of the calf muscles is common in femoropliteal 
occlusive disease. In the present studies, intermittent claudication was 
described as “disabling” to the patient in many cases. The preoperative 
walking distance was referred in meters as reported by the patients. Thus, the 
exact walking distance was not described in meters as initial or absolute 
claudication distance. Since 2002, we have routinely performed threadmill 
testing in the outpatient clinic in order to obtain more detailed information. 
This diagnostic tool gives more liable information under standardised 
conditions (44). 
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3.3.3.2    Critical ischaemia  
Critical ischaemia (study III, IV and V) was defined as either rest pain 
(Fontaine Stage 3) or tissue loss, i.e. ulcer or gangrene (Fontaine Stage 4) in 
agreement with the criteria in the Second European Consensus Document on 
Chronic Critical leg ischaemia (45). However, some cases with rest pain may 
not have had true critical limb ischaemia, due to the lack of Doppler toe 
pressure measurements in the present study (45). Toe pressure measurement 
was introduced in our department in 2001, and is now a routine investigation 
in the management of critical limb ischaemia. Toe pressure measurement is 
particularly important in diabetic patients and elderly patients in whom ankle 
pressure measurements may be overestimated in 5-15 % of cases due to tunica 
media sclerosis (46).  
 
3.3.4 Angiographic run-off score  
(Study III and IV). Run-off score was based on the number of patent 
crural arteries reaching the ankle, as seen on the preoperative angiogram. It 
was defined as good (> 1 patent artery) or poor (one patent artery or less). In 
study III, 45 out of 99 limbs had poor run-off score. In twelve cases the 
angiography was lost. In study IV, run-off score was recorded in 82 out of 87 
cases. In three cases, the angiogram was missing at the time of the study and 
two operations were performed without a preoperative angiography. 
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3.4 Preoperative investigations 
3.4.1 Clinical assessment. Patients whom the surgeon found to be fit for surgery 
were operated. There was no protocol for routine preoperative cardiac 
assessment.  
3.4.2 Ankle-brachial pressure measurements. Ankle-brachial pressure 
measurements were done as standard preoperative assessment. A resting 
ankle-arm index < 0.9 was considered significant. This finding is diagnostic 
for the presence of peripheral arterial disease with a sensitivity of 95 % and a 
specificity of 99 % (47-49). 
3.4.3 Digital Subtraction Angiography (DSA). DSA was routinely performed 
preoperatively. This was done with puncture of either common femoral artery. 
A catheter was then placed in the abdominal aorta by Seldinger technique 
(50,51). Contrast was injected and aortobifemoral angiography was performed. 
 
3.5 Surgical procedures 
3.5.1 Prosthetic above-knee femoropopliteal bypass (Studies I – V).  
3.5.1.1   Surgical technique. All operations were done under epidural anesthesia. 
The surgical technique was uniform, with an end-to-side anastomosis between 
graft and native artery both proximally and distally (Figure 3). Distal end-to-
side- anastomosis has been compared with end-to-end technique in a 
prospective randomised trial and the results of these two techniques were 
similar with respect to patency. However, in one study, major amputations 
after bypass failure were required more frequently for limbs with end-to-end 
anastomosis, probably due to occlusion of arterial branches cranial to the distal 
anastomosis when a distal end-to-end anastomosis is performed (52). 
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3.5.1.2   Prosthetic material. The majority of 108 PTFE-grafts were Gore-Tex® 
(W.L.Gore & Associates, Flagstaff, Ariz, USA) and most of the 144 polyester-
grafts were Unigraft® (B Braun, Melsungen, Germany). However, a small 
number of grafts from other manufacturers were used during the study period. 
PTFE grafts were used during the first four years of the study period, and 
polyester grafts were used latterly. The first polyester grafts used in our 
department were non-impregnated. However, the vast majority of the polyester 
grafts were impregnated. In study IV, the graft diameter was 6 mm in 68 (78 
%) cases and 8 mm in 19 cases (22 %). 
Figure 3. A polyester graft implanted 
as bypass from the common femoral 
artery to the above-knee popliteal 
artery in the right leg. 
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3.5.1.3   Heparin before clamping. Before 1999, rheomacrodex was given 
intravenously to prevent arterial thrombosis during surgery. After 1999, 
heparin (5000 IU) was administered intravenously before the common femoral 
artery was clamped. The Heparin dosage given is in agreement with 
established practise in Scandinavia. A subtherapeutic dosage may have been 
given in some cases, especially in obese patients. Alternatively, a weight-
based heparin protocol may be administered.  
3.5.1.4       Antithrombotic prophylaxis. LMWH 2500 IU daily was administered 
subcutaneuosly to low- and medium-risk patients whereas high-risk patients 
received a dosage of 5000 IU daily. 
3.5.1.5          Antibiotic prophylaxis. From 1990 to 1999, prophylaxis of cefuroxime 
1.5 g was administered intravenously three times during the day of surgery 
with the first dosage given at induction of anaesthesia. From 1999, the 
antibiotic was changed to 2 g of cephalotin given in a similar way. 
 
3.5.2 Reoperative/redo surgery. Reoperative surgery was defined as a new 
prosthetic bypass in cases with previous graft failure and was considered and 
analysed as a risk factor (Study I). A total of 17 cases underwent reoperative 
surgery. All of these were done for intermittent claudication. Surgical redo 
procedures were defined as re-opening occluded grafts. This was done 
surgically by an incision over the distal graft. The graft was incised and the 
thrombectomy was performed with a rubbered or un-rubbered graft 
thrombectomy catheter. 
3.5.3 Revisions for anastomotic stenoses. After graft thrombectomy, the area of 
the anastomoses was assessed intraluminally. Anastomotic revision was done 
in all cases found to have an anastomosis-related stenosis. 
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3.5.4 Revisions for infections. The choice of surgical treatment is dependent on 
whether the whole graft was infected or only part of it, and of the clinical 
response to the antibiotic treatment. Revision for graft infection was defined as 
surgical revision of the tissue surrounding the graft but leaving the graft in 
situ. 
3.5.5 Graft excision. (Study I) Excision of the graft was defined as complete 
removal of the graft. Excision of infected grafts was performed in selected 
cases with or without graft replacement. 
3.5.6 Amputation. (Study I, III and V). Major amputations were recorded. Major 
amputations were defined as above-knee, through-knee and below-knee 
amputations. Thus, minor amputations as toe and forefoot amputations were 
not recorded. No cases were treated with Syme’s operation. 
 
3.6 Endovascular procedures 
3.6.1 Percutaneous transluminal angioplasty (PTA) 
PTA (studies II-V) is a minimally invasive technique for angiographically 
guided vascular interventions, first described by Dotter and Judkins in 1964 
(53), in which the angioplasty was performed with coaxial catheters. Gruntzig 
et al developed a catheter with a central balloon, which is the method still used 
today (54,55). By the use of Seldinger technique, a balloon-catheter is inserted 
into the artery over a guidewire and inflated at the arterial lesion, with the 
intent to increase the internal diameter. This treatment method is typically 
applied on stenoses and short occlusions (< 3-4 cm). In the present study, PTA 
was done for significant graft-related stenotic lesions (> 50 % lumen 
reduction). All of these stenoses were localised at the distal anastomoses. 
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3.6.2 Intraarterial thrombolysis 
(Study III and V). Intraarterial thrombolysis was done selectively for graft 
thrombosis. Selection criteria for choice of treatment were not clearly defined. 
However, patients unfit for thrombolysis according to the recommendations of 
the Working Party on Thrombolysis in the Management of Limb Ischaemia 
were selected for thrombectomy (56). The procedures were performed with 
crossover technique. The catheter was placed with continuous release of the 
thrombolytic agent into the proximal portion of the thrombus. The catheter 
was distalised as the thrombus dissolved. Until April 1997 Streptokinase (40 
000 IE/hour) was routinely used as thrombolytic agent. Therafter, recombinant 
human tissue-type plasminogen activator (rt-PA) was preferred. A bolus dose 
of 5 mg was injected into the thrombus, followed by a continuous infusion (1.5 
mg/hour). Cases complicated with distal embolisation were managed with 
further thrombolysis or endovascular aspiration. Percutaneous transluminal 
angioplasty (PTA) after thrombolysis was done in cases with a significant 
stenotic lesion at the distal anastomosis. In the present studies, there were no 
cases with significant stenoses in the proximal anastomoses.  
 
3.7 Transit time flowmetry 
3.7.1 Theoretical background and principles 
The first transit time flowmeter was described by Franklin et al (57) and 
Plass (58), but the theoretical basis for transit time flow measurement was 
described by Drost in 1978 (59). The transit time flow probe consists of two 
small piezoelectric crystals, one upstream and one downstream, mounted in a 
common tip that can be placed around the vessel without constricting it 
(Figure 4). The front of the probe is flat, and a small metallic reflector bracket 
 27
is mounted opposite the crystals. Each crystal can produce a wide ultrasound 
beam covering the entire vessel diameter. The transit times are measured for 
an ultrasound pulse signal emitted from the upstream crystal to arrive at the 
downstream crystal via the reflector and for a signal from the downstream 
crystal to reach the upstream electrode via the reflector. Since ultrasound 
travels faster when it is transmitted in the same direction as flow, a small time 
difference (Δ t) for the two signals as expressed in a shift of phase (down to 
picosecond values) can be determined. All blood flow velocity components are 
detected by the wide ultrasound beam, and transit time determinations are 
sampled at all points across the vessel diameter, so the measurement of volume 
blood flow is theoretically independent of the blood flow velocity profile due 
to this integration procedure (60). 
      
 
 
 
 
 
 
 
 
3.7.2 Validity and reliability 
Transit time flowmetry has been demonstrated to be a reliable method 
with reproducible results (61-63). This method does not have the major 
disadavantages that characterise the previous methods for blood-flow 
Figure 4. A transit time flow probe with two small piezoelectric 
crystals, mounted in a common tip placed around the vessel.  
Blue signal: t1 
Green signal: t2 
t1 > t2  (∆t) 
piezoelectric crystals 
Reflector 
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measurements; electromagnetic flowmetry and the Doppler flowmetry. In 
electromagnetic flowmetry, the measurement is influenced by the hematocrit, 
the wessel wall thickness as well as the angle between the probe and the 
vessel. The flow signal is unstable and the flowmeter has to be recalibrated 
continuously (64). The Doppler flowmeter is sensitive to the alignment 
between probe and vessel. This is not the case for transit time technique, but 
acoustic fluid (gel, blood or saline water) must be present between the probe 
and the vessel to ensure good acoustic coupling. 
 
3.7.3 Clinical relevance 
The method has been widely used in vascular surgery since its 
introduction in 1983(61). The clinical value of using transit time flowmetry is 
described by Lundell(65). Low values of blood-flow measurements has been 
reported to be predictive of early graft occlusion in infrainguinal bypass 
bypass surgery (66-70). A flow of ≤ 50 ml/min has been associated with 
failure of above-knee prostheses (69,70). Low levels of maximum capacity 
flow, i.e. the peak flow after intragraft injection of papaverine) have also been 
reported to be predictive of reduced graft patency in vein grafts (66). The 
relationship between papaverine flow and femoropopliteal prosthetic graft 
patency has not been reported previously. 
 
3.7.4 Limitations of flowmetry in prosthetic bypass surgery 
Blood flow in prostheses can only be measured indirectly with transit 
time flowmetry, by measuring flow in inflow or outflow arteries. This is due to 
the attenuation of Doppler signals in air trapped inside the prosthesis wall (60). 
Outflow can be measured by placing the probe distally to the reconstruction, 
which was done in most cases in the present studies. Alternatively, inflow can 
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be measured by placing the probe proximal to the reconstruction. In the 
present study, this was done in cases with technical difficulties in placing the 
probe around the popliteal artery. In these patients, the profunda femoral artery 
was clamped while measuring flow in the common femoral artery. If a 
proximal part of the superficial femoral artery was open, a higher flow volume 
than the actual graft flow may have been recorded. Likewise, flow 
measurements in the popliteal artery may not have reflected the actual graft 
flow volume in the femoropopliteal graft. Because the anastomoses in the 
present series were created end-to-side, some degree of retrograde flow from 
the popliteal artery may have occurred in some patients. If this was the case, 
the recorded flow was lower than the actual graft flow. 
 
3.7.5 Definitions 
Basal flow: The flow measurement after declamping, before injection of 
papaverine. 
Papaverine flow: The peak flow, i.e. the maximum capacity flow, after 
injection of papaverine. 
 
3.7.6 The use of flowmetry in the present study 
A transit time Doppler flowmeter (CardioMed 1000, Medi-Stim AS, 
Oslo, Norway) was used for blood-flow measurements. The probes were 
precalibrated by the manufacturer and the measurement error was less than 10 
%. Flow was measured with the probe placed around the popliteal artery below 
the distal anastomosis. Where lack of exposure prohibited flow measurement 
of the popliteal artery, flow was measured in the common femoral artery while 
clamping the profunda femoral artery. Flow was measured before and after a 
40 mg intragraft injection of papaverine. 
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3.8 Antiplatelet medication 
Aspirin 160 mg daily was given postoperatively on a permanent basis if 
tolerated. No other antithrombotic agent was given. Whether or not the 
patients were compliant to this medication was not investigated. 
 
3.9 Complications 
3.9.1 Registered complications were recorded in the database registry. A selection 
was made as listed below. Occlusion and death within 30 days of surgery were 
recorded according to the suggested standards for reporting (71). Local 
complications (lymphatic complications, surgical site infections, graft 
infection) and general complications (myocardial infarction, stroke, death 
within 30 days) were registered.  In addition, all graft infections during follow-
up were recorded (Study I). 
 
3.9.2 Lymphatic complications. 
Lymphatic fistula was defined as at least two days of persistent leakage of 
clear fluid from the incision (72), whereas a lymphocele was diagnosed in 
cases with a subcutaneous fluid collection in the abscence of hematoma or a 
surgical site infection (72). 
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3.9.3 Local infections. 
Szilagyi’s clinical classification of infection was applied (73). 
Grade 1. Surgical site infection confined to dermis. 
Grade2. Infection of the subcutaneus tissue without involving the graft. 
Grade 3. Graft infection was diagnosed in cases with a tender, 
erythematous, pulsatile mass overlying the prosthetic material, 
and in cases with exposed graft, or if there was persistent 
drainage from a sinus tract close to the prosthetic material. 
 
3.9.4 Occlusion within 30 days.  
Graft occlusion occurring within 30 days of surgery was considered a 
complication and was recorded accordingly. Early graft occlusion is usually 
due to technical failure or subjection of non-eligible patients for bypass 
surgery (74).  
 
3.9.5 Death within 30 days.  
This information is regarded reliable in the studies of this thesis, since 
the mortality data were obtained from The Registrars Office for Death and 
Birth. 
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3.10 Follow-up and endpoints 
3.10.1 Protocol for follow-up 
Follow-up was done with duplex scanning, ankle-brachial pressure 
measurement and clinical assessment 1, 3, 6 and 12 months after surgery and 
annually thereafter. New procedures during follow-up warranted a new follow-
up protocol. 
3.10.2 DSA.  
Angiography was performed as preoperative diagnostic work-up in 
cases in need for intervention. 
3.10.3 Endpoints 
3.10.3.1 Paper I: Surgical site infection or graft infection. 
3.10.3.2 Paper II: The primary occlusion or death. 
3.10.3.3 Paper III: The primary occlusion, the terminal occlusion, major         
amputation, death. 
3.10.3.4 Paper IV: The primary occlusion. 
3.10.3.5 Paper V: The primary occlusion, terminal occlusion, major amputation. 
 
3.11 Statistics 
3.11.1 Survival 
Mortality data on the operated patients were obtained from The 
Registrars Office of Birth and Death. Death rate tables were obtained from a 
national database registry, Statistics Norway (75), and used to calculate the 
survival of a demographically matched population (i.e. the expected survival). 
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In cases with more than one operation per patient, the calculation of survival 
was based on the time of the first operation. Observed survival was compared 
with that of a demographically matched population. The relative survival was 
defined as the ratio of the observed survival to that of the expected. The 
Mantel-Haenschel test was applied to analyse the difference between observed 
and expected survival (76). 
 
3.11.2 Limb salvage.  
Limb salvage was defined as freedom from major amputation. 
 
3.11.3 Patency.  
The diagnosis of graft occlusion was based on duplex scanning or 
angiographic findings. The occlusion date was defined as either the time of 
verification of occlusion or recurrence of symptoms. The decision to reopen 
occluded grafts was based on the surgeon’s opinion on the possibility and 
importance of salvaging the graft. 
3.11.3.1   Primary patency. Primary patency was defined as freedom from 
occlusion without any procedures done on the graft. 
3.11.3.2   Primary assisted patency. This was defined as freedom from 
occlusion. Treatment of stenotic lesions may or may not have been performed.  
3.11.3.3   Secondary patency. Secondary patency was defined as an open 
graft which may have been subjected to one or more re-opening procedures. 
 
3.11.4 Analyses of survival, limb salvage and patency 
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3.11.4.1   Analyses of survival, limb salvage and patency rates. These 
analyses were carried out with the Product-limit method. The computations are 
performed each time a defined event happens, i.e. death, amputation or graft 
occlusion. The survival rates are presented as Kaplan-Meier curves where the 
decreasing survival rate is illustrated stepwise. The numbers of cases still at 
risk are indicated along the curves. This method is recommended for such 
analyses in vascular surgery (77).  
3.11.4.2   Univariate analyses. Univariate comparison of rates between 
subgroups was done with the log rank test. This test is a non-parametric 
method for testing the null-hypothesis that the groups compared are samples 
from equal populations with respect to survival, limb salvage or patency.  
3.11.4.3   Multivariate analyses. Multivariate analyses of the association 
between risk factors and survival, limb salvage and patency rates were 
performed with the Cox proportion hazard model (77).    
   Cox’ method is a “semi-parametric” approach – no 
particular distribution is assumed for the survival times, but an assumption is 
made that the effects of the different variables on survival, limb salvage or 
patency are constant over time and are additive. The intercorrelation of 
variables included in the analysis is explored, accounting for variable 
observation times. In the present context it means calculation accounting for 
the relative impact of concurrent diseases and other risk factors on survival, 
limb salvage or patency. Interpreting a Cox model involves exploring the 
coefficient for each explanatory variable. A positive regression coefficient (β) 
for an explanatory variable means that the hazard is higher, and thus the 
prognosis worse for higher values. Conversely, a negative regression 
coefficient implies a better prognosis for a higher value. The hazard ratio is 
Exp(β). 
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3.11.5 Categorical data 
The Fisher exact test was applied for comparison of categorical data. 
This test is considered more accurate than the standard Chi square test, 
especially for small sample sizes (78). 
3.11.6 Continuous data 
The Student t-test was used to compare continuous data.  The t-test is 
appropriate when you have continuous values in two groups and wish to test 
the difference of means (79). The Student’s t-test is a parametric test assuming 
a normal distribution. In this study, mean age differences between men and 
women are compared. 
3.11.7 Software program 
For paper I and II, the software ”Statistica 6.0” (Statsoft, Inc., Tulsa, 
OK, USA) was used for statistical computations. For paper III – V, the 
software “SPSS for Windows 13.0” (SPSS Inc. (2004), Illinois, USA) was used. 
3.11.8 Statistical significance 
Differences were considered statistically significant at p < 0.05. 
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4. General discussion 
 
4.1 General discussion 
4.1.1 Reporting standards.  
Suggested standards for reports dealing with lower extremity ischemia 
were published in 1986 in Journal of Vascular Surgery (71). In 1997, a 
revised edition of recommended standards was published (80). 
According to these, quite a number of issues need to be addressed: the 
degree of lower limb ischemia, outcome criteria, risk factors 
(comorbidity, run-off), death and complications. Grafts used should be 
reported with graft material, manufacturer, graft diameter and coating of 
the graft. Furthermore, operative techniques (anastomoses etc.) should 
be described. Thus, of the five studies in the present Thesis, study IV 
only satisfies the suggested standards. 
 
4.1.2 Treatment options for femoropopliteal occlusive disease 
4.1.2.1 Medical treatment. Modern medical treatment of lower limb ischemia 
consists of smoking cessation, systematic exercise and modification of 
risk factors for atherosclerosis including specific medication. This 
treatment may be described as “best medical treatment”. All patients 
with peripheral arterial disease should receive best medical treatment. 
This is documented below in this chapter. 
4.1.2.1.1  Smoking is discussed in 3.3.2. It is mandatory that smokers receive 
information on the great benefit of smoking cessation, i.e. the 
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magnitude of smoking as a risk factor for poor results after 
femoropopliteal bypass surgery.  
4.1.2.1.2  Excercise. Randomised controlled trials have proven that systematic 
exercise improves walking distance significantly in patients with 
intermittent claudication. According to a meta-analysis of such studies, 
walking distance may be improved approximately 150 % by 30 minutes 
walking exercise minimum three times per week (81). Thre preventive 
effect of exercise on risk of cardiovascular events is an extra bonus of 
this treatment (82,83).  
4.1.2.1.3  Medication. Aspirin is effective in preventing thromboembolic disease 
and patients with peripheral atherosclerosis should therefore receive a 
daily dosage of aspirin (84-87). Patients with have aspirin-intolerance 
should receive clopidogrel instead (86). Treatment with ACE-inhibitors 
reduces the risk of cardiovascular events by 25 % per year in patients 
with peripheral vascular disease (88,89). According to the HPS-study, 
the same reduction in cardiovascuar morbidity can be achieved with the 
use of statins (90). Statins are reported to reduce inflammation in 
atherosclerotic plaques as well as plaque-thickness (91). Use of statins 
has also been proven to improve walking capacity in claudicants 
(92,93). Patients with chronic limb ischaemia would thus benefit from a 
triplet basis medication: an antiplatelet agent, an ACE-inhibitor and a 
statin. This medication regimen has been standard treatment in our 
department since 2002.                       
  Antithrombotic medication following bypass surgery is 
discussed in 4.1.3. 
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4.1.2.2 Endovascular treatment. 
 
4.1.2.2.1 PTA.  PTA can be used for treatment of arterial stenoses and short (3-4 
cm) occlusions. This method is not suitable for treatment of long lesions 
due to low technical success rate and poor patency and should be 
reserved for TASC-A and –B lesions (94). 
4.1.2.2.2 Subintimal angioplasty. This technique was first describe by Bolia et 
al. in 1990 (95). In 1994, the same group published long-term results, 
suggesting subintimal angioplasty as a useful alternative to bypass 
surgery (96). The common femoral artery is punctured on the ipsilateral 
side. Subintimal entry is achieved by pushing a 5 French straight 
angiography catheter into the lesion. The occluded segment is then 
traversed with a .035`` hydrophilic guidewire (Terumo). The tip of the 
guidewire is looped during the passage and followed by a 5 French 
straight catheter. After reentry at the distal end of the lesion, the 
subintimal passage is dilated with either a 5 or 6 mm balloon 
angioplasty catheter. A few centres have reported good results using 
subintimal angioplasty (97-100). However, patients in these studies 
often had intermittent claudication and follow-up has not always been 
with duplex (4). Other centres have experienced poorer results after 
subintimal angioplasty (4,101). It appears that this treatment method is 
only successful in the hands of few.  
4.1.2.2.3 Metal stents. Metal stents became commercially available in the early 
1990’s. Many trials have been performed to investigate the results of 
treatment with stents for femoropopliteal occlusive disease. The results 
reported are often in terms of 12-monts patency rates of 50 – 60 % 
(102,103). These results are not superior to treatment with PTA alone 
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(104). In our department, a stent is used only for salvaging a technical 
unsuccessful PTA due to recoil or dissection. The outcomes of these 
salvaging procedures have been proven similar to PTA and stent as a 
primary procedure (105).  
4.1.2.2.4 Absorbable metal stents. Biodegradable stents basically made of 
magnesium have been used in treating infrapopliteal lesions with 
acceptable short-term results. This stent permits the use of MRI in 
follow-up after the stent has been absorbed (106). Long-term results are 
lacking, but this stent may have a potential in treating atherosclerotic 
lesions in the superficial femoral and popliteal artery. 
4.1.2.2.5 Drug-eluting stents. Drug-eluting stents became available for use in 
peripheral vascular surgery in 2003. Basically, the stent has an inner 
coating in which a slow-releasing drug is deposited. Examples of drugs 
used for this purpose are sirolimus and tacrolimus. Drug-eluting stents 
were expected to improve performance compared with the metal stents 
available on the market for some years. This optimism was based on the 
promising reports on drug-eluting stents in the coronary arteries. 
However, randomised controlled trials have revealed patency in the 
same range as for metal stents without the drug coating (107,107). 
Furthermore, drug-eluting stents do not seem effective in treating in-
stent restenosis (108). 
4.1.2.2.6 Hemobahn®/Viabahn®. These devices are long metal stents with an 
inner covering of PTFE. Initially, this device was manufactured as 
Hemobahn®. In 2004, the device was slightly modified, and the name 
was changed to Viabahn®. Long occlusions are supposed to be the 
primary indication for covered stents in femoropopliteal occlusive 
disease. A one-year patency rate of 58 % has been reported in a 
feasibility study (109). As for subintimal angioplasty, good results seem 
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to be achieved only in the hands of the few, which may explain the not 
so widespread use of the technique. 
4.1.2.2.7 Other endovascular treatment methods. Publications do exist of 
treatment methods such as the excimer laser (110) and endovascular 
atherectomy (111) for infrainguinal atherosclerotic lesions. 
Furthermore, endovascular cryotherapy (112) and brachytherapy (113) 
has been used in combination with PTA. However, none of the above-
mentioned methods are proven effective and their use is not widespread. 
 
4.1.2.3 Surgical treatment. 
4.1.2.3.1 Bypass surgery. In these procedures, a vein or a prosthetic graft is used 
as conduit. The technique for prosthetic graft bypass is described in 
3.5.1. Vein grafts may be used either in situ or in the reversed fashion. 
Veins must have good quality in order to be accepted as conduit in 
bypass surgery. Vein bypass is somewhat more time-consuming as 
compared with prosthetic bypass. A more detailed presentation of vein 
grafting is considered beyond the scope of this thesis. 
4.1.2.4 Open endarterectomy of the superficial femoral artery. This 
treatment option is seldom used, although acceptable long-term results 
have been reported for lesions localised in the adductor canal (114). 
Thus, this method should be remembered as an alternative for selected 
cases with critical limb ischaemia, in which other treatment options not 
are available. 
4.1.2.5 Remote endarterectomy (ring-stripping a.m. Moll). This procedure is 
carried out with a groin incision only, with open access to the common 
femoral artery. The atherosclerotic plaque is removed by the use of a 
modified ring stripper, cutting the intima at the distal end. The 
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procedure includes placement of a covered stent at the end of the 
endarterectomy (115). This method has been reported with acceptable 
results up to 18 months (116). However, remote endarterectomy is not 
in widespread use, and acceptable results have only been reported from 
a few centres. Thus, it appears that this method, like subintimal 
angioplasty and Hemobahn®/Viabahn®, works well in the hands of few 
only. 
 
4.1.3 Antithrombotic therapy after bypass surgery 
Antiplatelet agents improve graft patency, especially for 
prosthetic grafts (117). Patients with aspirin intolerance should 
therefore receive clopidogrel (117). Warfarin has been reported to have 
an effect in preventing occlusion in infrainguinal vein grafts, but not in 
prosthetic grafts(118). Long-term injection of heparin was in 1988 
proven to reduce neointimal hyperplasia in an animal study(119). In 
1994, results came forth from a trial where 200 femoropopliteal 
bypasses were randomised to either three months treatment with 
subcutaneous low-molecular-weight heparin (LMWH) or low-dose 
aspirin and dipyramidole (120). After 12 months, patency was 87 % in 
the LMWH-group and 72 % in the antiplatelet group. The difference 
was statistically significant. However, the publication of these results 
did not alter clinical practice. In our department, LMWH is given for 
four weeks after surgery in cases believed to be at high risk for 
occlusion. 
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4.1.4 Choice of treatment for femoropopliteal occlusive disease – 
conservative treatment, endovascular treatment or bypass surgery? 
4.1.4.1 Intermittent claudication. Invasive treatment for intermittent 
claudication has hitherto not been found to improve survival of patients 
with peripheral atherosclerosis. However, a secondary health effect on 
cardiac function might occur in some patients due to improved walking 
capacity. Treatment of intermittent claudication may enhance quality-
of-life but to a variable extent. The effect seems unrelated to the initial 
and absolute claudication distances, but more to in which manner the 
condition affects the patient. Therefore, patients need to be evaluated 
individually. There is a need for more studies on how quality-of-life 
actually is affected by intermittent claudication (121). 
For intermittent claudication caused by lesions in the femoropopliteal 
segment, there is consensus on a conservative strategy (122-124). This 
is due to the benign nature of intermittent claudication, with an 
amputation risk of approximately 1 % per year (125,126). In fact, even 
very low complication rates after intervention may lead to an 
amputation risk exceeding that of the natural history. 
Subintimal angioplasty has limited durability, but performs better 
when done for intermittent claudication as compared with critical 
ischaemia (4,97). Subintimal angioplasty is accepted in our department 
as the first treatment option for severely disabled claudicants with 
unilateral disease. However, the patients must have had a stable disease 
and been on medical treatment for at least six months. In cases with a 
failing subintimal angioplasty, bypass is done on patients with severely 
disabling intermittent claudication. Autologous vein is preferred over 
prosthesis as conduit in above-knee femoropopliteal bypass in our 
department, and prostheses are used only when a suitable vein is 
lacking. 
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4.1.4.2 Critical ischaemia. A recently published randomised controlled trial 
comparing endovascular treatment with bypass surgery for critical 
ischemia (BASIL) revealed long-term results (i.e. > 2 years) in favour 
of bypass surgery (127). The results from this study indicate that bypass 
should be preferred to endovascular procedures for patients with life 
expectancy beyond two years. Bypass-surgery-first and PTA-first 
strategy was associated with similar outcome in terms of amputation-
free survival up to two years after treatment. In the short term (< 12 
months), surgery was more expensive than angioplasty. Patients with 
critical leg ischaemia are often elderly with extensive comorbidity, and 
open surgery might not always be an option. Thus, the two treatment 
modalities, endovascular treatment versus bypass surgery, appear in 
many cases not to be two competitive but rather complementary 
treatments options. 
At Haukeland University Hospital, subintimal angioplasty is preferred 
as the treatment choice for critical limb ischaemia in cases with 
anatomically suitable lesions. Duplex assessment of the reconstruction 
is performed within a week, due to the low patency rates of subintimal 
angioplasty.  In cases of a failed subintimal angioplasty, a 
femoropopliteal vein bypass is the next step. Prosthetic bypass is only 
done in cases lacking suitable vein. 
 
4.1.5 Graft-types for bypass 
4.1.5.1 PTFE. Polytetrafluorene (Goretex®) prostheses were used during the 
first four years of the studies included in this Thesis. PTFE is 
manufactured with and without circular rings to support and maintain an 
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open lumen in cases with low diameter, low flow or substantial external 
pressure forces. 
4.1.5.2 Polyester. Polyester graft was the preferred conduit for prosthetic 
bypass in our department from 1994 until now. Polyester grafts may be 
knitted or woven, and impregnated or not. The majority of prostheses in 
the present study were of polyester (dacron) and most of them were 
impregnated, except during the first years of the study.  
4.1.5.3 Human umbilical vein (HUV). HUV-grafts are reported to have long-
term patency rates in the same range as autologous vein (128). 
However, a main disadvantage of HUV is the formation of anurysms, 
which may occur in 20 % at five years (129). 
4.1.5.4 Modifications of prosthetic grafts. Some prostheses are manufactured 
with an additional external or internal layer, for instance a gelatin-layer 
or an external covering. PTFE-grafts are now available with an inner 
layer containing immobilised heparin. Polyester grafts are also available 
with silver-impregnation and some grafts may be soaked in antibiotics 
before implantation, for instance rifampicin, provided there is a gelatin 
coating for deposition and binding of the drug.  
4.1.5.5 Autologous vein. Vein as conduit may be used in situ or in the reversed 
fashion. Preferably, the great saphenous vein is used. However, the 
lesser saphenous vein, the Giacomini vein or even veins from the upper 
extremity may be used with acceptable long-term results (130-132). 
4.1.5.6 Autologous artery. An excised occluded artery may be used as bypass 
after ring stripping, for example the superficial femoral artery. 
4.1.5.7 Homologous artery or vein.  Arteries and veins have been harvested 
from donors of transplant organs and used as conduits in peripheral 
vascular reconstructions (133). Alloveins harvested during varicose vein 
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stripping have also been used (134). However, the use of homografts in 
peripheral vascular surgery is an ethical dilemma, especially since 
prosthetic grafts are readily available. Therefore, the use of homografts 
is not considered acceptable practice in peripheral vascular surgery. 
 
 
4.1.6 Prosthetic graft diameter 
Whether or not graft diameter influences the results of above-
knee prosthetic bypass has been studied previously. Three-year results 
from a prospective, randomised multi-center trial comparing PTFE and 
polyester grafts were published in 1997 (1), and five-year results were 
published in 2000 (25). The three-year patency rates for small (< 7 mm) 
and large grafts (> 7 mm) were 60 % and 80 % respectively. Grafts with 
diameter less than 7 mm also had inferior patency at five years 
compared to grafts with diameter above 7 mm. However, the difference 
was found to be sex-dependant. The five-year primary patency rates for 
men with small and large grafts were 37.9 and 69.1%, respectively. 
Similar comparisons for women revealed five-year patency rates of 45 
% for both small and large grafts. 
Since 1997, 8 mm grafts have been used as standard size for 
above-knee femoropopliteal prostheses at Haukeland University 
Hospital, except for cases with small-caliber arteries, usually women, in 
which 6 mm grafts were chosen. Before 1997, 6 mm grafts were mainly 
used.  Thus, the majority of the grafts in the present study are 6 mm. It 
is not known if the use of larger grafts in men would have influenced 
the results in the present study. 
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4.1.7 The use of above-knee prosthetic femoropopliteal bypass  
4.1.7.1 Graft type. In the present studies, 144 were polyester and 108 were 
PTFE. There were no differences in results between the graft types, nor 
were there any differences in the distribution of complications. The 
same finding has been reported previously (1,26). Mathisen et al 
demonstrated that PTFE was more prone to platelet aggregation on the 
luminal surface as compared with polyester (135). However, this 
remains to be proven in a clinical setting. 
4.1.7.2 The use of femoropopliteal grafts at Haukeland University Hospital. 
The total numbers of femoropopliteal bypasses performed at Haukeland 
University Hospital during the study period was 388, of which 279 were 
above-knee bypasses and 109 were below-knee. In above-knee 
femoropopliteal bypass, a vein was used as conduit in 27 cases, whereas 
prosthesis was used in 252 cases. For below-knee femoropopliteal 
bypass, an autologous vein was used in 75 cases, HUV in two cases, a 
composite graft in 13 cases and a prostetic graft in 19 cases. 
4.1.7.3 Time trends. The yearly number of prosthetic bypass procedures 
inclined to a peak in 1994-1995 and then declined (Figure 2). The 
reduction in yearly operations is concomitant in time with the 
introduction of subintimal angioplasty in our department, which was in 
1997. From 1997 throughout 2001, a total of 124 femoropopliteal 
subintimal angioplasties were done. 
4.1.7.4 Prosthetic grafts versus autologous vein. Similar results for prosthetic 
grafts versus autologous vein used as conduit in the above-knee position 
have been reported (136). However, a metaanalysis published in 2004 
concluded that vein is superior to prosthesis in the femoropopliteal 
above-knee position (137).  
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4.1.7.5 Sparing the saphenous vein. Sparing the saphenous vein for later 
coronary bypass has been used as an argument for using prosthetic 
grafts. However, only 1 % of patients undergoing infrainguinal bypass 
surgery will later need the vein for this or other purposes (138). 
4.1.7.6 Advantages and disadvantages of prosthetic grafts. The main 
advantages of prosthetic grafts are that they are readily available for use 
and that the operation becomes less time-consuming as compared with 
vein bypass. The main disadvantages are the susceptibility to infection 
and the limited durability with respect to patency. 
4.1.7.7 Impact of flow on the fate of femoropopliteal prostheses. In the present 
study (Paper IV), basal flow was not related to patency but papaverine 
flow was. High-flow reconstructions like aortoiliac or aortofemoral 
bypass have good long-term results, whereas infrainguinal bypass 
operations have limited durability. An experimental study revealed that 
high-flow arterial reconstructions develop less intimal hyperplasia than 
low-flow reconstructions do and conversion from a low-flow bypass to 
a high-flow bypass in a baboon model showed regression of neointimal 
hyperplasia (139). 
 
4.1.8 Graft surveillance.  
The results in studies III and V indicate a possible gain from 
surveillance and that a long observation period is necessary to achieve 
full overview.  A possible gain from graft surveillance has been 
reported previously. A randomised study revealed significant better 
patency of grafts subjected to a duplex surveillance program due to 
detection of stenoses subsequently successfully treated (140). However, 
surveillance of vein grafts has been reported not to improve limb 
salvage in another randomised study (141).  
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The majority of occluded grafts in the present study were not 
identified with significant graft-related stenotic lesions. Occlusion may 
be attributed to the thrombogenicity of the prostheses, but also to risk 
factors influencing patency, as demonstrated in the present studies. 
Perhaps grafts with stenoses of less than 50 % lumen diameter reduction 
are prone to graft occlusion, and that these stenoses should be more 
liberally revised. However, data to prove this are not available. 
The results in the present studies underline the need of a long 
observation period to achieve full overview. Examples are late graft 
infections in Study I and the increasing difference in patency over time 
between smokers and non-smokers (Study III and IV). 
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5. Results and discussion of specific papers 
 
5.1 Paper I. Local infections after above-knee prosthetic 
femoropopliteal bypass for intermittent claudication.  
5.1.1 Results. Local infections were found during follow-up in 
approximately 20 % of the operations, surgical site infection in 8 % and 
graft infection in 12 %. Lymphatic complications were recognised after 
13 % of the operations. The risk of developing a local infection was 
significantly correlated with postoperative lymph fistula, and 
reoperative surgery was associated with graft infection. Graft infection 
caused by Staphylococcus aureus always warranted surgery, either local 
revision or graft excision.  
5.1.2 Discussion. The infection rate in this study is higher than several 
previous reports. The high infection rate is partly explained by the wide 
definition of infectious complication applied in this study and by the 
long observation period, revealing four very late graft infections. The 
results suggest a conservative attitude towards prosthetic 
femoropopliteal bypass for intermittent claudication. 
 
5.2 Paper II: The impact of comorbidity on long-term results of above-
knee prosthetic femoropopliteal bypass for intermittent 
claudication. 
5.2.1  Results. The five-year survival was 77 %, which is significantly lower 
than the survival of a demographically matched population (85 %). 
Preoperative serum-creatinine > 125 μmol/l was significantly associated 
with reduced survival (p < 0.01). The assisted primary patency rates 
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were 62 % at two years and 44 % at five years. The five-year patency 
rate for smokers was 24 % versus 67 % for non-smokers (p < 0.01). A 
previous history of a cerebral infarction was significantly associated 
with reduced graft patency (p = 0.02). 
5.2.2 Discussion. Smokers should be treated more conservatively due to their 
inferior patency rates. In contrast to what was seen in non-smokers, the 
grafts in smokers continued to occlude beyond eighteen months 
postoperatively and the difference between patency rates of grafts in 
smokers and non-smokers increased with time. The reduced graft 
patency rates of patients with a preoperative history of a cerebral insult 
need further studies to be verified.  
5.3 Paper III: The impact of patient characteristics on long-term 
results of above-knee prosthetic femoropopliteal bypass for critical 
ischaemia. 
5.3.1  Results. The 30-day mortality rate was 5.5 %. The 2- and 5-year 
survival was 72 % and 42 %, respectively. Twenty-seven limbs were 
subjected to major amputations during follow-up. The limb salvage 
rates at 2 and 5 years were 83 % and 73 %. The 2 and 5-year assisted 
primary patency rates for smokers were 38 % versus 62 % for non-
smokers. Smoking and tissue loss were significantly associated with 
reduced secondary patency rates on multivariate analysis. 
5.3.2 Discussion. The 5.5 % 30-day mortality rate (six patients) may be 
reduced by a more careful selection of patients for surgery. Five patients 
died from a coronary infarction and one from a cerebral stroke. This 
suggests a possible benefit from preoperative cardiac assessment, or at 
least a troponine assessment. Smokers had inferior patency rates. As 
demonstrated in study II, the difference between patency rates of grafts 
 51
in smokers and non-smokers increased with time, but in this study the 
difference became apparent after one year postoperatively.  
 
 
 
5.4 Paper IV: Flow measurement before and after intragraft 
papaverine injection in above-knee prosthetic femoropopliteal 
bypass. 
5.4.1 Results. Basal flow measurements were not related to patency. The 2- 
and 5-year patency rates for grafts with a papaverine flow < 500 ml/min 
were 48 % and 18 % compared with 66 % and 52 % for grafts with a 
papaverine flow ≥ 500 ml/min. These differences were statistically 
significant (p = 0.012, hazard ratio 2.6). Two- and 5-year patency rates 
for smokers vs non-smokers were 44 % and 18 % vs 69 % and 54 %. 
The patency rates for patients with poor vs good run-off were 42 % and 
27 % vs 69 % and 31 %. Smoking (p = 0.008, hazard ratio 2.75) and 
poor run-off score (p = 0.009, hazard ratio 2.38) were found to be 
independent risk factors for reduced patency rates. Poor run-off score 
did not correlate with low values of measured basal or papaverine flow. 
5.4.2 Discussion. Additional antithrombotic medication and frequent follow-
up for grafts with a papaverine flow < 500 ml/min may be considered. 
The inferior patency of smokers and patients with poor run-off indicate 
that prosthetic bypass is less suitable for these groups of patients. 
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5.5 Paper V: The outcome of occluded above-knee femoropopliteal 
prostheses implanted for critical ischaemia.  
5.5.1 Results. The one-year patency rate for redo procedures was 12 %. 
Cases in which a pre-existing anastomotic stenosis was identified and 
treated fared significantly better, although only 4/10 of these cases were 
alive with open graft one year postoperatively. 
5.5.2 Discussion. The results were disappointing. Some patients may benefit 
from a redo procedure if a stenotic lesion is known prior to graft 
occlusion. All other patients with a need for intervention should be 
treated with a new arterial reconstruction or amputation. 
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6. Conclusions 
From this study the following conclusion might be drawn: 
 
- The results regarding survival, limb salvage and patency correspond 
with previous reports. 
- A long observation period is necessary to achieve full overview of 
complications and of the impact of risk factors on the results. 
- Infectious complications after prosthetic femoropopliteal bypass were 
higher than in previous reports. 
- A selective approach should be taken towards excision of infected 
femoropopliteal prostheses, and surgical treatment should be 
individualised according to the clinical presentation of the graft 
infection and the type of bacteriae involved. 
- A conservative attitude is recommended towards above-knee prosthetic 
femoropopliteal bypass for intermittent claudication. 
- Smokers have inferior patency rates when operated for intermittent 
claudication as well as for critical ischaemia, indicating that prosthetic 
femoropopliteal bypass is not very suitable for smokers.  
- The reduced graft patency rates of patients with a history of a cerebral 
insult operated for intermittent claudication need further studies to be 
verified. 
- Patients with intermittent claudication and renal impairment reveal poor 
survival, indicating renal impairment as a relative contraindication for 
surgical treatment of intermittent claudication. 
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- The poor secondary patency rates for smokers as well as for patients 
with tissue loss suggest that these patients may benefit from alternative 
treatment modalities instead of reopening an occluded bypass.  
- Papaverine flow of < 500 ml/min is associated with reduced mid- and 
long-term patency rates of above-knee femoropopliteal prosthetic 
bypass. 
- Additional antithrombotic medication and frequent follow-up may be 
considered for grafts with a papaverine flow less than 500 ml/min. 
- The inferior patency rates of patients with poor run-off indicate that 
prosthetic bypass is less suitable for these patients. 
- Redo procedures for occluded grafts originally implanted for critical 
ischaemia are of limited value and cannot be recommended except in 
cases with a proven graft-related stenosis. Other cases in need of re-
intervention should be treated by amputation or a new arterial 
reconstruction.  
- When offering an above-knee prosthetic femoropopliteal bypass as 
treatment, the following must be evaluated: patient comorbidity, degree 
of ischaemia, affection on quality-of-life and anatomical-pathological 
considerations as the atherosclerotic lesion and the angiographic run-off 
score. 
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Risk factor Reduced patency 
Smoking +++ 
Papaverine flow < 500 ml/min ++ 
Critical ischaemia vs intermittent 
claudication 
++ 
Poor run-off score ++ 
Tissue loss vs rest pain + 
Preoperative cerebral insult + 
 
Table III. Table III demonstrates the relationship between studied risk factors 
and reduced patency of above-knee prosthetic femoropopliteal bypass. 
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7. Future perspectives 
 
The findings in this study suggest that the following topics might be studied in order 
to improve the results of above-knee prosthetic femoropopliteal bypass surgery: 
 
7.1 Therapeutical advances in antithrombotic medication. A possible effect of 
additional platelet inhibition on patency might be studied in a randomised trial, 
i.e. aspirin + placebo versus aspirin + clopidogrel. This would be of particular 
interest for the subgroups with poor results such as low flow grafts, smokers, 
critical ischaemia, poor run-off and tissue loss. An ongoing study (the 
CASPAR-study) investigates this. 
7.2 Advances in risk modification. Smoking cessation has the greatest potential for 
graft patency improval. Varenicline (nicotine acetylcholine receptor agonist) is 
reported to give better results with respect to smoking cessation as compared 
with bupropione (142). The impact of active anti-smoking therapy might be 
subjected to clinical investigation in peripheral bypass surgery. Since the study 
period (i.e. after 2001), medical treatment of atherosclerosis has been 
implemented as standard treatment in vascular surgery whether patients are 
operated on or not. Whether or not such anti-atherosclerotic treatment would 
have affected the results in the present study is not known. The possible 
benefit of preoperative cardiological assessment in improving the results after 
peripheral bypass surgery might be tested in a clinical trial. Advances in 
detection of and management of diabetes mellitus may also improve results 
after peripheral bypass surgery. As discussed previously, we are currently 
investigating this in a prospective trial at Haukeland University Hospital. 
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7.3 More aggressive treatment of graft-related stenoses. It is not obvious that a 50 
% lumen diameter reduction in the anastomosic region is a clear-cut indication 
for anastomosis-revision. Graft-related stenoses less than 50 % might have the 
potential to cause graft occlusion. This may be studied in a clinical trial, 
although such a trial might be difficult to organise due to the low number of 
these operations performed. 
7.4 Development in graft engineering. The subgroups with even the best results 
after above-knee femoropopliteal bypass surgery demonstrate the need for 
grafts with better performance. Reports with promising results after using a 
new PTFE-graft with an interior coating of immobilised heparin have been 
published (143-145). However, these are only observational studies on 
selected patients. External scaffolding has been proven effective in 
experimental studies (146,147). Recently, a PEG-hirudin/iloprost coating was 
proven effective in prevention of intimal hyperplasia formation in a canine 
model(148). 
7.5 Studies on Quality-of-life. This would be particularly helpful in selecting 
patients for surgery and it might influence indications for intervention in the 
future. However, the indication for prosthetic femoropopliteal bypass would 
probably still be severe disabling intermittent claudication in cases lacking 
vein, unless progress in graft engineering with substantially improved graft 
performance will occur. 
7.6 Vacuum Assisted closure (VAC). VAC gives the opportunity for in-situ 
treatment of graft infection (149). This treatment alternative may reduce the 
need for surgical procedures, especially graft excision, in cases with graft 
infection (149). 
7.7 Advances in endovascular techniques and devices. Improvements in devices 
for endovascular treatment might enhance results of these procedures, and 
perhaps reduce the need for surgical treatment. 
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8. Strengths and weaknesses 
 
8.1 Strengths 
8.1.1  Prospectively recorded data. Most of the data analysed were 
prospectively registered in a database. 
8.1.2 Surveillance program. All cases entered a protocol for regular follow-
up which included duplex ultrasound and ankle-brachial pressure 
measurement. This allows an acceptable precision in determining the 
time of events. 
8.1.3 Sample size. Two-hundred-and-fifty-two prostheses implanted on 237 
patients constitute a relatively large material. 
8.1.4 Surgical technique. The creation of anastomoses during graft 
implantation was uniform. This reduces the possibility of variations in 
surgical technique influencing the results. 
8.1.5 PTA of graft-related stenoses. The definition of success of PTA 
performed on a graft-related stenosis was based on the evaluation of 
completion angiography. However, these cases entered a new follow-up 
protocol including duplex investigation, ensuring that residual stenoses 
were not present. 
8.1.6 Long follow-up. The long follow-up period in studies I – IV provides a 
true picture of complications and patency rates. 
8.1.7 Accuracy of mortality data. The use of data from the Registrars office 
for births and deaths leaves a high degree of accuracy. 
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8.2 Weaknesses 
8.2.1  Retrospective analyses. Studies I – V are retrospectively analysed. 
Thus, selection bias may influence results. Furthermore, the case series 
is uncontrolled. 
8.2.2 Single-center experience. Usually single-center studies do not include 
large scale number of patients, which may be the case in multicenter 
studies.  
8.2.3 Preoperative investigations. Preoperative assessments were based upon 
statements made by the patients, ankle-brachial pressure measurements 
and angiography. Threadmill testing of patients with intermittent 
claudication and toe pressure measurements in patients with critical 
ischaemia have been used during the later years. This allows a more 
objective evaluation. 
8.2.4 Sample size. The small sample size and few events, especially in study I 
and V, may be considered a weakness. 
8.2.5 Postoperative medication. There are no data confirming the use of 
aspirin postoperatively. The only information given is that aspiring was 
administered to all patients except in cases with aspirin intolerance. 
Whether or not the patients were compliant to this medication and how 
this may have influenced the results are not known. 
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9.  Errata 
 
 
Paper I 
In study I, chronic lung disease was recorded. This information is unaccurate, since 
the patients had COPD, which was actually registered in the vascular database. This 
is corrected in study II – V. 
 
Paper II 
None errors have been detected in this paper. 
 
Paper III 
Page 2, line 20:”All operations were done by specialist in vascular surgery”. This is 
not correct due to the fact that some of the operations were performed by surgeons-
in-training. 
Page 3, Graft patency, third paragraph: “The association between smoking and 
reduced secondary patency was also significant in univariate analysis (P = 0.20, log 
rank test)”. The p-value is incorrect. The correct p-value is 0.020. 
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Paper IV 
Abstract, line 1 and 2: “The 2- and 5-year patency rates for grafts with a papaverine 
flow ≤ 500 ml/min….” should be corrected to: “…a papaverine flow < 500 ml/min. 
Patients and Methods, 1. Paragraph: Numbers of 6 and 8 mm grafts: Numbers should 
be reversed.  
 
Paper V 
Abstract, results, line 1: “restored” should be replaced with “restore”. 
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10.  Appendix  
 
 
Type Anatomical lesions 
TASC-A 1. Single stenosis < 3 cm, not at the origin of the superficial femoral        
artery or at the distal popliteal artery 
TASC-B 2. Single stenosis 3-5 cm, not involving the distal popliteal artery 
3. Heavily calcified stenoses < 3cm 
4. Multiple lesions < 3 cm (stenoses or occlusions) 
5. Single or multiple lesions in the abscence of continous tibial run-off 
to improve inflow for distal surgical bypass 
TASC-C 6. Single stenosis or occlusion > 5 cm 
7. Multiple stenoses or occlusions, each 3-5 cm, with or without heavy 
calcification 
TASC-D 8. Complete common femoral artery or superficial artery occlusions, or 
complete popliteal and proximal trifurcation occlusions 
 
Table I. Morphological stratification of femoropopliteal atherosclerotic 
lesions according to the TASC document (11). 
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Stage Clinical presentation 
Stage 1 No symptoms 
Stage 2 Intermittent claudication 
Stage 3 Rest pain due to critical ischaemia 
Stage 4 Tissue loss (ulcer or gangrena) 
 
Table II. Fontaine classification of lower limb ischemia in  
non-diabetic patients.  
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